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In 1995, Penfold et al reported a pilot study of intra-
vitreal injection of 4 mg of triamcinolone acetonide
(IVTA) to treat exudative age-related macular degen-
eration with encouraging results [1]. Thereafter,
intravitreal injection of triamcinolone acetonide
became a useful therapeutic option for many condi-
tions, including ocular inflammatory diseases [2],
retinal veno-occlusive disease [3], diabetic macular
edema [4] and ocular choroidal neovascularization [5].
One of the ocular side effects of corticosteroids is the
elevation of intraocular pressure (IOP) [6,7]. As the
expansion of indications and use of IVTA increases, the
incidence of corticosteroid-induced glaucoma associated
with IVTA will become more commonly encountered
by ophthalmologists. The purpose of this study was
to investigate the incidence of significant IOP eleva-
tion, the magnitude of the IOP rise after IVTA and the
interval between IVTA and the subsequent increase
in IOP in Taiwanese patients.
METHODS
Patient selection
A retrospective chart review was performed between
September 2004 and December 2005. Initial preop-
erative evaluation included visual acuity, slit-lamp 
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The purpose of this study was to investigate the incidence and timing of elevation in intraocular
pressure (IOP) after intravitreal injection of triamcinolone acetonide (IVTA). This was a retro-
spective observational case series that included 52 eyes from 52 patients. All patients received
intravitreal injection with 4 mg of triamcinolone acetonide. Significant IOP elevation was defined
as pressure greater than 21 mmHg. There were 26 males and 26 females included in this study.
The mean age was 59.4 years. The mean IOP at baseline and postoperative mean highest IOP were
14.6 mmHg and 21.5 mmHg, respectively. There were 19 (36.5%) patients who experienced signif-
icant IOP elevation at a mean of 26.0 days after IVTA. IOP was well-controlled by topical
antiglaucoma medication in 17 of these 19 patients. IOP elevation after intravitreal injection with
4 mg of triamcinolone acetonide is not a rare finding. This phenomenon usually starts approxi-
mately 1 month after IVTA. Patients considering this treatment should be fully informed of this
known adverse effect.
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biomicroscopy, indirect ophthalmoscopy, IOP mea-
surement by Goldmann applanation tonometry and
glaucoma survey by a glaucoma specialist in our
department. Eyes with any type of glaucoma (open-
angle glaucoma, angle-closure glaucoma, secondary
glaucoma associated with its original eye disease) at
baseline were excluded from this study. All patients
gave written informed consent. For those patients who
received IVTA in both eyes, only the first eye to
receive an injection was included in this study.
Surgical procedure
Under topical anesthesia, IVTA was performed under
sterile conditions in the operation room with an oper-
ation microscope. Povidone-iodine (Saint-iodine®;
Patron, Gangshan, Taiwan) was applied before IVTA.
Then, the patient was completely draped. We used 
a lid speculum to open the eye. Paracentesis into the
anterior chamber was performed and some aqueous
fluid was aspirated using a 26-gauge needle with 
a 1.0-mL tuberculin syringe to reduce the volume of
the eye. We used triamcinolone acetonide 40 mg/mL
suspension (Kenalog; Bristol-Myers Squibb, New
Brunswick, NJ, USA) directly from the vial without
attempting to isolate the supernatant from the crystals.
The injection of crystalline triamcinolone acetonide
(4mg in 0.1mL) into the vitreous cavity was performed
using a sharp 27-gauge needle through the inferior
temporal pars plana [2,3,5,8]. A prophylactic antibiotic
eye drop was then applied.
Postoperative follow-up
Thereafter, patients were examined on the first day, 
1 week, 2 weeks and 4 weeks after the injection, fol-
lowed by reevaluation at monthly intervals. If post-
operative IOP exceeded 21 mmHg, which was defined
as significant IOP elevation, topical antiglaucoma ther-
apy was prescribed. If IOP continued to be elevated
despite maximal medical treatment, filtering surgery
was indicated.
Statistical analysis
Statistical analysis was performed using JMP statistical
software version 5.1.2 (SAS Institute Inc., Cary, NC,
USA). The IOP at baseline and postoperative maximal
IOP were compared using a paired t test. Analyses of
descriptive data (postoperatively significant IOP ele-
vation vs. gender, ocular diagnosis for IVTA, diabetes
mellitus and hypertension) were performed using
Pearson’s χ2 test. The level of significance was 0.05
(two-sided) in all statistical tests.
RESULTS
Demographic data
This study included 52 eyes from 52 patients. There
were 26 males and 26 females included in this study.
The mean age was 59.4 ± 11.3 years. Regarding sys-
temic disease, 25 patients had diabetes mellitus and
26 had essential hypertension. Preoperative ocular
diagnosis included diabetic cystoid macular edema
(30.8%), central retinal vein occlusion (23.1%), branch
retinal vein occlusion (23.1%) and other ocular diag-
noses that included neovascular age-related macular
degeneration and uveitis-associated macular edema.
The mean follow-up time was 42.1 ± 6.5 weeks.
Detailed demographic data are shown in Table 1.
Postoperative follow-up
The mean IOP at baseline was 14.6 ± 2.9 mmHg
(range, 9–20 mmHg). There was a significant increase
(p<0.001) in the mean maximal IOP of 21.5±8.1mmHg
(range, 11–49 mmHg) postoperatively. The mean
maximal pressure increase was 6.9 ± 7.9 mmHg
(range, −2–36 mmHg). During the follow-up period,
there were 19 eyes (36.5%) that experienced a signifi-
cant IOP elevation (i.e. IOP > 21 mmHg after IVTA).
Among these 19 patients, the timing of significant IOP
Table 1. Demographic data of the 52 patients (52 eyes)*
Gender
Male 26 (50.0)
Female 26 (50.0)
Age (yr) 59.4 ± 11.3 (18–78)
Medical history
Diabetes mellitus 25 (48.1)
Hypertension 26 (50.0)
Reason for treatment
Diabetic macular edema 16 (30.7)
Central retinal vein occlusion 12 (23.1)
Branch retinal vein occlusion 12 (23.1)
Others 12 (23.1)
Follow-up period (wk) 42.1 ± 6.5 (32–60)
Number of follow-up visits 13.0 ± 1.5 (11–16)
*Data presented as mean (%) or mean ± standard deviation
(range).
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elevation occurred at a mean of 26.0 ± 9.8 days (range,
14–60 days) after IVTA. By χ2 analysis, significant
IOP elevation was not significantly associated with
gender, ocular diagnosis for IVTA, diabetes mellitus
or hypertension. Detailed data on IOPs at baseline
and during the postoperative period are shown in
Table 2.
Figure 1 shows the timing of significant IOP ele-
vation during the follow-up period. The rise in IOP
occurred most frequently between 2 weeks and 
4 weeks after injection. After 60 days postoperatively,
no new cases of glaucoma were observed. Figure 2
demonstrates the IOP measurements of eyes with
IOP>21mmHg and those with IOP≤21mmHg during
the follow-up period. The highest IOP usually
occurred 1 month after injection, in both groups.
Among the 19 patients who experienced signifi-
cant IOP elevation, 17 (89.4%) could be well controlled
with a mean of 1.7 ± 1.1 (range, 1–4) antiglaucoma
medications (e.g. β-blockers, α2-agonists). Despite
maximal medical therapy, the IOPs of the other two
patients remained high and these patients required
filtering surgery. After operation, the IOPs of both
eyes lowered to within the normal range without
additional antiglaucoma medication.
DISCUSSION
It has been known for many years that increased IOP
can occur as a consequence of oral, intravenous,
inhaled, topical, periocular or intravitreal corticosteroid
therapy [9–13]. If it is not recognized or well-treated,
subsequent glaucomatous optic neuropathy might
develop. The aim of this study was to investigate the
incidence and timing of significant IOP elevation
after intravitreal injection of 4 mg triamcinolone ace-
tonide. In our study, none of the patients had a diag-
nosis of glaucoma before the injection. The overall
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Figure 1. Survival plot shows the proportion of eyes with intraocular pressure (IOP) > 21 mmHg with time after the injection. 
Eyes experiencing IOP > 21 mmHg usually occurred between 14 and 28 days postoperatively.
Table 2. Intraocular pressure (IOP) at baseline and
throughout the follow-up period*
IOP at baseline 14.6 ± 2.9 (9–20) mmHg
Postoperative IOP
Maximal postoperative IOP 21.5±8.1 (11–49) mmHg
Maximal IOP increase 6.9 ± 7.9 (−2–36) mmHg
IOP > 21 mmHg 19 eyes (36.5%)
Days to IOP > 21 mmHg 26.0 ± 9.8 (14–60)
*Data presented as mean ± standard deviation (range).
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incidence of significant IOP elevation after IVTA was
36.5% occurring at a mean of approximately 4 weeks.
Beer et al reported a mean elimination half-life of 18.6
days in five nonvitrectomized patients after intravit-
real injection of 4 mg triamcinolone acetonide [14].
Our result of significant IOP elevation at a mean of
26.0 days indicates that the adverse effect of triamci-
nolone acetonide may extend more than one half-life
after the injection. The slope of a survival curve stabi-
lized 8 weeks after IVTA, suggesting that patients
had low risk for significant IOP elevation 2 months
after IVTA. In patients who did not experience signif-
icant IOP elevation, most had maximal IOP 4 weeks
after IVTA. This suggests that patients receiving
IVTA should at least have regular follow-ups in the
first 1–2 months after the injection.
In a study by Jonas et al, 41.2% of eyes experi-
enced a pressure greater than 21 mmHg with the rise
occurring from 1 week to 2 months after the injection
[15]. This timing of IOP rise was similar to our
results. However, the incidence was higher than our
results. The possible explanation for the higher inci-
dence of significant IOP elevation might be the
higher dosage of triamcinolone acetonide (20 mg vs.
4 mg) used in their study. The mechanism of cortico-
steroid-induced ocular hypertension is increased
aqueous outflow resistance [16]. Corticosteroids can
induce physical and mechanical changes in the
microstructure of the trabecular meshwork causing
an increase in the deposition of substances in the 
trabecular meshwork, thereby decreasing aqueous
outflow [17].
There is an increasing concern about the preserva-
tive vehicle used to administer triamcinolone aceto-
nide. Benzyl alcohol has been implicated in cases 
of sterile endophthalmitis after intravitreal injection
[18,19]. Mauricio et al reported that noninfectious 
endophthalmitis was observed significantly more
often in eyes treated with triamcinolone acetonide
containing preservatives than in those treated with
preservative-free triamcinolone acetonide, but both
groups had similar rates of postoperative ocular
hypertension [20]. Different techniques to reduce the
amount of benzyl alcohol in commercially prepared
triamcinolone acetonide, including sedimentation,
centrifugation and filter techniques, have been
reported in an attempt to reduce toxicity [21–23]. All
of these different techniques employed effectively
reduced the concentration of benzyl alcohol [20].
However, in most studies, a dose of 4 mg with preser-
vatives was widely used [24].
Most patients with significant IOP elevations after
IVTA can be well managed with topical antiglau-
coma medication. According to our results, 89.4% of
patients who experienced significant IOP elevation
were successfully controlled by topical eye drops.
There were only two patients who received filtering
surgery to control IOP. However, traditional filtering
surgery is not the only option. Agrawal et al reported
pars plana vitrectomy with removal of intraocular
triamcinolone acetonide particles in the vitreous cav-
ity to treat eyes with intractable IOP elevation [25].
In conclusion, according to our results, intravit-
real injection of 4 mg of triamcinolone acetonide can
lead to significant IOP elevation in approximately
one-third of patients, occurring at a mean of 4 weeks
after injection. Patients who are treated with this pro-
cedure should be fully informed about this common
side effect, and regular follow-up for IOP in the first 
2 months is usually necessary.
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Figure 2. Intraocular pressure (IOP) measurements at baseline
and after injection in eyes with postoperative IOP > 21 mmHg
versus eyes with postoperative IOP ≤ 21 mmHg. The highest 
IOP was usually measured 1 month after injection in both
groups.
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